Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
NCT04239014 · AstraZeneca · PHASE2 · withdrawn · last registry update 2021-03-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the VIOLETTE study (NCT03330847) investigating the combination of ceralasertib and Olaparib, where study closure was recommended due to insufficient efficacy.” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-08Results posted on the registry: Janssen Research & Development, LLC, Niraparib (NCT02854436)
- 2022-02-09Results posted on the registry: Bristol-Myers Squibb, nivolumab + docetaxel (NCT03338790)
- 2021-12-29Phase 3 first posted: AstraZeneca, olaparib + abiraterone acetate (NCT05171816)
- 2021-12-08Results posted on the registry: AstraZeneca, Olaparib + Placebo (NCT02032823)
- 2021-09-28Phase 3 first posted: Pfizer, Avelumab + Lorlatanib (NCT05059522)
- 2021-08-17Phase 3 first posted: AGO Study Group, Carboplatin + Paclitaxel (NCT05009082)
- 2021-07-12Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Paclitaxel (NCT01386385)
- 2021-05-13Phase 3 first posted: AstraZeneca, Olaparib (NCT04884360)
- 2021-05-10Results posted on the registry: Tesaro, Inc., Niraparib + TSR-042 (NCT03307785)
- 2021-03-29Phase 3 first posted: Pfizer, talazoparib plus enzalutamide + Placebo plus enzalutamide (NCT04821622)
- 2021-03-12Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cediranib Maleate (NCT02446600)
- 2021-01-28Phase 3 first posted: Novartis Pharmaceuticals, Alpelisib + Olaparib (NCT04729387)
- 2020-11-10Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab 200 mg + Pembrolizumab 400 mg (NCT04624204)
- 2020-09-29Results posted on the registry: National Cancer Institute (NCI), Fluorouracil + Fluorouracil (NCT02890355)
- 2020-08-04Phase 3 first posted: Janssen Research & Development, LLC, Niraparib+ Abiraterone acetate fixed dose combination (FDC) + Abiraterone acetate (AA) (NCT04497844)
- 2020-07-22Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Olaparib (NCT01116648)
- 2020-07-17Phase 3 first posted: GlaxoSmithKline, Niraparib + Pembrolizumab (NCT04475939)
- 2020-07-02Phase 3 first posted: Alliance for Clinical Trials in Oncology, Enzalutamide + Rucaparib camsylate (NCT04455750)
- 2020-06-11Results posted on the registry: Tesaro, Inc., Niraparib + Placebo (NCT02655016)
- 2020-06-09Phase 3 first posted: AstraZeneca, Olaparib (NCT04421963)
- 2020-05-08Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Olaparib (NCT04380636)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision